These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 36127731)
1. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731 [TBL] [Abstract][Full Text] [Related]
2. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955 [TBL] [Abstract][Full Text] [Related]
3. Testing algorithm for identification of patients with TRK fusion cancer. Penault-Llorca F; Rudzinski ER; Sepulveda AR J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837 [TBL] [Abstract][Full Text] [Related]
4. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer. Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952 [TBL] [Abstract][Full Text] [Related]
7. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127 [TBL] [Abstract][Full Text] [Related]
8. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025 [TBL] [Abstract][Full Text] [Related]
9. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853 [TBL] [Abstract][Full Text] [Related]
10. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer. Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252 [TBL] [Abstract][Full Text] [Related]
11. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer. Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589 [TBL] [Abstract][Full Text] [Related]
12. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719 [TBL] [Abstract][Full Text] [Related]
13. Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase. Eyerer FIR; Bradshaw G; Vasalos P; Laser JS; Chang CC; Kim AS; Olson DR; Paler RJ; Rosenbaum JN; Walk EE; Willis JE; Yao J; Yohe SL Arch Pathol Lab Med; 2023 Aug; 147(8):872-884. PubMed ID: 36508682 [TBL] [Abstract][Full Text] [Related]
14. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
15. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. Rudzinski ER; Hechtman J; Roy-Chowdhuri S; Rudolph M; Lockwood CM; Silvertown J; Wierzbinska J; Shen K; Norenberg R; Nogai H; Hong DS; Drilon A; Laetsch TW Cancer Genet; 2022 Jan; 260-261():46-52. PubMed ID: 34929613 [TBL] [Abstract][Full Text] [Related]
17. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951 [TBL] [Abstract][Full Text] [Related]
18. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380 [TBL] [Abstract][Full Text] [Related]
19. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform. Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612 [No Abstract] [Full Text] [Related]
20. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]